Capabilities by Industry: Healthcare

Greenhill has considerable transaction experience and a global network of corporate relationships in the Healthcare sector.  Our Managing Directors and professionals in North America, the United Kingdom, Continental Europe, Australia, Brazil and Japan have executed many of the most significant and complex transactions for some of the leading companies in the industry.

In addition to traditional M&A transactions, our team has extensive experience advising on complex partnering and licensing transactions.

Our experience in the Healthcare industry encompasses the following sub-sectors: healthcare services; life science tools; medical devices and services; branded, specialty and generic pharmaceuticals and biotechnology. 

Below we highlight a few of the transactions on which we have advised in this area:

Recent Transactions

28-Jul-16
$80 million
United States flag
Target: 

BioD, LLC

United States flag
Acquiror: 
Derma Sciences, Inc.

Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.

28-Jun-16
$NA
Israel flag
Target: 

U.S. rights to an authorized generic version of Adderall XR

United States flag
Acquiror: 
Prasco Laboratories

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights  to an authorized generic version of Adderall XR

28-Jun-16
$652 million
Israel flag
Target: 

U.S. rights to 37 approved and 5 pipeline generic products

Australia flag
Acquiror: 
Mayne Pharma Group Limited

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights  to 42 generic products

21-Jun-16
$586 million
Israel flag
Target: 

U.S. rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.

United States flag
Acquiror: 
Impax Laboratories, Inc.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.

20-Jun-16
$NA
Israel flag
Target: 

U.S. rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Zydus Cadila

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to 2 generic drug products to Zydus Cadila

16-Jun-16
$40 million
Israel flag
Target: 

U.S. rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.

United States flag
Acquiror: 
Sagent Pharmaceuticals, Inc.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to 5 generic injectable drug products  to Sagent Pharmaceuticals, Inc. 

15-Jun-16
$414 million
United States flag
Target: 

Aegerion Pharmaceuticals

Canada flag
Acquiror: 
QLT Inc.

Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization

11-Jun-16
$350 million
Israel flag
Target: 

U.S. rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Dr. Reddy’s Laboratories

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to 8 generic drug products to Dr. Reddy’s Laboratories

04-May-16
$NA
United States flag
Target: 

Portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs

United States flag
Acquiror: 
Ligand Pharmaceuticals

Advised CorMatrix Cardiovascular, a leading medical device company with a differentiated extracellular matrix technology, on the sale of a portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs

19-Apr-16
$NA
United States flag
Target: 

Total Care Medicaid Plan

United States flag
Acquiror: 
Molina Healthcare, Inc.

Advised Molina Healthcare Inc., a provider of managed health care services under the Medicaid and Medicare programs, on the acquisition of Universal American’s Total Care Medicaid plan

07-Mar-16
$NA
Germany flag
Target: 

Boehringer Ingelheim

United States flag
Acquiror: 
AbbVie

Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.

19-Jan-16
$NA
Brazil flag
Target: 

Recepta Biopharma

Brazil flag
Acquiror: 
Inova Empresa Fundo de Investimento em Participações

Advised Recepta Biopharma on a capital raise

01-Dec-15
$NA
United Kingdom flag
Target: 

Allied Healthcare

Germany flag
Acquiror: 
AURELIUS Investments

Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments

29-Oct-15
$275 million
United States flag
Target: 

Aesynt, Inc.

United States flag
Acquiror: 
Omnicell, Inc.

Advised Omnicell, Inc., a leading supplier to health systems of automation solutions and business analytics software for medication and supply management, on the acquisition of Aesynt, Inc., a provider of integrated pharmacy automation solutions for hospitals and health systems

27-Jul-15
$40.5 billion
Ireland flag
Target: 

Allergan Generics

Israel flag
Acquiror: 
Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business

06-Jul-15
$910 million
United States flag
Target: 

Altegra Health, Inc.

United States flag
Acquiror: 
Emdeon Inc.

Advised Emdeon, a leading healthcare information technology company, on the acquisition of Altegra Health, a national provider of technology and intervention platforms for value-based healthcare

08-Jun-15
$45 million
Canada flag
Target: 

Aralez Pharmaceuticals Inc.

Canada flag
Acquiror: 
QLT Inc.

Advised QLT Inc. on its strategic equity investment in Aralez Pharmaceuticals Inc., a newly formed global specialty pharmaceutical company resulting from the business combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc., and the special distribution of the Aralez shares to QLT shareholders.

02-Jun-15
$NA
United Kingdom flag
Target: 

Portfolio of GlaxoSmithKline plc consumer and OTC brands

United States flag
Acquiror: 
Perrigo Company plc

Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc

21-Apr-15
$963 million
flag not available
Target: 

Refinancing of syndicated bank debt facilities

Australia flag
Acquiror: 
Primary Health Care

Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities

11-Aug-14
$NA
United States flag
Target: 

MannKind Corporation

France flag
Acquiror: 
Sanofi

Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.

05-Aug-14
$1.3 billion
U.S.A., Germany flags
Target: 

Siemens Health Services

United States flag
Acquiror: 
Cerner Corporation

Advised Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.

28-Jul-14
$90 million
Australia flag
Target: 

Clinuvel Pharmaceuticals Limited

United States flag
Acquiror: 
Retrophin, Inc.

Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases

18-Feb-14
$25.1 billion
United States flag
Target: 

Forest Laboratories Inc.

Ireland flag
Acquiror: 
Actavis plc

Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.

05-Feb-14
$NA
Sweden flag
Target: 

Unfors Raysafe AB

United States flag
Acquiror: 
Fluke Biomedical Corporation

Advised the Sixth Swedish National Pension Fund on the sale of Unfors Raysafe AB, a provider of easy-to-use products that help to reduce unnecessary radiation exposure, to Fluke Biomedical Corp., a subsidiary of Danaher Corp. that manufactures biomedical test and simulation products

18-Dec-13
$NA
United States flag
Target: 

Fidelis SeniorCare Inc. (Michigan Heath Plan)

United States flag
Acquiror: 
Centene Corporation

Advised Fidelis SeniorCare Inc., a healthcare provider focused on the care of the elderly, on the sale of a majority of its SecureCare Michigan health plan to Centene Corporation, a managed care provider focused on the Medicaid space

Pages

show all